

PRESS RELEASE

Oasmias cancer drug one step closer the American market

Between 1-4th of November the clinical results for Oasmias cancer drug Paclical® Vet will be presented at the annual Veterinary Cancer Society Congress in Florida.

- I am very pleased that our abstract has been accepted for presentation at the Annual Veterinary Cancer Society Congress in Florida. It means that we are going to reach an audience with the best competence in the subject. This will also give us the possibility to discuss and involve the most prominent, says Henrik von Euler, principal veterinarian.

- The congress in USA is a milestone for Oasmia. Our participation is an important step in Oasmias registration process but most of all for the American veterinary market. In that case Oasmia will be the first company in the world with a registered cytostaticum for dogs, says Julian Aleksov, CEO at Oasmia.

Paclical® Vet has showed surprisingly good results in dogs with cancer where the previous alternative a few years ago was euthanization. Today there are 140 million dogs in EU and USA.

More information is available at www.ngm.se or www.oasmia.com

For further information please contact: info@oasmia.com or call: +46 (0) 18 50 54 40

Oasmia Pharmaceutical AB is a pharmaceutical company that specialises in the treatment of severe diseases. A pharmaceutical company based on the latest concepts in bio-organic chemistry. The main idea is to improve the treatment of serious diseases. Primarily, this development is in oncology and treatment with cytostatics but Oasmia also conducts research in antibiotics, asthma and neurological diseases. Oasmia has in-house production capacity of pharmaceuticals for clinical trials, both company related and others. Oasmia has developed several products based on existing pharmaceuticals in a new environment, which leads to whole new solutions for cancer treatment. These products give Oasmia a solid product portfolio within oncology with several products in clinical or pre-clinical phase. Oasmia is listed on NGM Equity.